Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Culling The Pipeline: An Analysis Of Biogen's Discontinued Programs

  • News

You may also be interested in...



Biogen Continues To Plot New Course In Naming Two Key Executives. But Is Independence Part Of The Plan?

The big biotech announces Steve Holtzman, former chairman of Infinity, as head of corporate development, with Doug Williams, former CEO of ZymoGenetics stepping in as exec VP of R&D.

Biogen Idec Lays Off 13 Percent of Staff, Retrenches Around Multiple Sclerosis

Saying his new company is spread "a mile wide and an inch deep," Biogen Idec Inc.'s CEO George Scangos, PhD, affirmed Nov. 3 that the big biotech firm will drastically pare its pipeline, cut 13% of staff, and refocus its efforts around its historic strength – its multiple sclerosis franchise.

Biogen Idec/Acorda Strike Licensing Deal For MS Candidate Fampridine-SR

Biogen gains revenues, Acorda gets a strong partner well-entrenched in the EU MS market.

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS052849

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By